

MEDISCA[®] NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/15/2013; Page 1

Suggested	Mycophenolate Mofetil 50 mg/mL Oral Liquid (Suspension, 100 mL)	EIM	E 004 106-2
Formula	Mycophenolate Moletil 50 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 004 106v3
Formina			

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Mycophenolate Mofetil, USP	5.000	g				
Propylene Glycol, USP	5.0	mL				
Medisca Oral Suspend (Suspending Vehicle)	25.0	mL				
Cherry Syrup (Humco)	q.s. to 100.0	mL				

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light Sensitive (protect from light whenever possible):

Hygroscopic (protect from moisture whenever possible):

Suggested Preparatory Guidelines

Non-Sterile Prepara	tion Sterile Preparation
<u>Processing Error /</u> <u>Testing Considerations</u> :	To account for processing error considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients.
Special Instruction:	Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.
	This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

Mycophenolate Mofetil, Propylene Glycol

Propylene Glycol



MEDISCA[®] NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/15/2013; Page 2

Suggested Formula	Mycophenolate Mofetil 50 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 004 106v3	
----------------------	---	-----	-------------	--

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) :	Processing Error	Qty. to measure
Mycophenolate Mofetil, USP §	5.000	g			
Propylene Glycol, USP §	5.0	mL			
Medisca Oral Suspend (Suspending Vehicle)	25.0	mL			
Cherry Syrup (Humco)	q.s. to 100.0	mL	©		

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

Preparatory Instruction

1. **Powder-liquid preparation:**

- A. Triturate the Mycophenolate Mofentil to form a fine, homogeneous powder.
- B. Levigate the fine, homogeneous powder (Step 1A) with the Propylene Glycol.

End result: Homogeneous liquid-like dispersion.

2. Medium integration:

A. Incrementally add the homogeneous liquid-like dispersion (Step 1B) to the Oral Suspend (Suspending Vehicle).

Specifications: Continuously mix, using high shear mixing techniques.

End result: Homogeneous liquid-like dispersion.

3. **Filling to volume:**

A. Add Cherry Syrup (Humco) to the mixture to fill to the required batch size (100.0 mL *plus* processing error adjustments).

Specifications: Continuously mix, using high shear mixing techniques.

End result: Homogeneous liquid-like dispersion.



4.

MEDISCA[®] NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/15/2013; Page 3

Suggested Formula	Mycophenolate Mofetil 50 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 004 106v3
----------------------	---	-----	-------------

Product transfer:

A. Transfer the final product into the specified dispensing container (see "Packaging requirements").

<u>Note</u>: Continuously mix the final product during the transfer process into the recommended dispensing containers in order to maintain homogeneity.

SUGGESTED PRESENTATION

Estima Beyond-Use D		14 days, refrigerated, as per USP.	Packa Requirem		 Tightly closed, light-resistant dispensing bottle. To be administered with a metered dose- measuring device.
Auxiliary Labels	1	Use as directed. Do not exceed dose.	l prescribed	6	Shake well before use.
	2	Keep out of reach of children.		7	Cap tightly after use.
	3	Protect from light.		8	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.
	4	May impair mental and/or phys Use care when operating machinery.	•	9	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.
	5	Keep refrigerated. Do not freeze.			
Pharmacist Instructions	Ad	d any auxiliary labels specific to the	he API to the	dispe	nsing container as deemed necessary.
Patient Instructions	Co	ntact your pharmacist in the event	of adverse re	actior	18.



MEDISCA[®] NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

10/15/2013; Page 4

	ggested	Mycophenolate Mofetil 50 mg/mL Oral Liquid (Suspension, 100 mL)	FIN	F 004 106v		
]	Formula	Trycophenolate Woreth 50 mg/mil Oral Erquid (Suspension, 100 mL)	1111	1 004 1007		
ER	ENCES	S				
1.		taramanan R, McCombs JR, Zuckerman S et al. Stability of mycophenolate mofetil asion. <i>Ann Pharmacother</i> 1998; 32(7-8): 755-757.	as an exter	nporaneous		
2.	Susper Americ	nsions. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Com</i> can Pharmaceutical Association; 2008: 209.	pounding T	hird Edition.		
3.	Cellce	pt IV. In: Canadian Pharmacists Association. Compendium of Pharmacists and Spe	cialties, 20	09. 479.		
4.		ene Glycol. In: Rowe RC. Handbook of Pharmaceutical Excipients, 6 th Edition. An inition; 2009: 592.	nerican Pha	rmaceutical		
5.	Mycophenolate Mofentil In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 1836.					
6.	Mycophenolic Acid (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #6327.					
7.	Mycophenolate Mofetil (Monograph). United States Pharmacopeia XXXII / National Formulary 27. Rockville, MD. US Pharmacopeial Convention, Inc. 2009: 3015.					
8.	Mycophenolate Systemic. Thomson Micromedex. USP DI – Drug Information for the Health Care Professional, 26 th Edition. Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 2141.					
9.		795>. United States Pharmacopeia XXXII / National Formulary 27. Rockville, MD ntion, Inc. 2009: 314.). US Pharn	nacopeial		
10.	• 1	phenolate Mofetil. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations</i> , aceutical Association; 2009: 398.	4th Edition	<i>ı</i> . American		

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW.